ESTRO 2024 - Abstract Book

S38 ESTRO 2024 the risks of using inappropriate PROMs, or an inappropriate implementation strategy, and aid RTTs and researchers to choose the most appropriate PROM for their patient cohort. Invited Speaker

3337

FLASH: Towards the clinic and implications for the RTT

Frederic Duclos

CHUV, Radio oncology, Lausanne, Switzerland

Abstract:

The clinical translation of FLASH Radiotherapy was initiated in our department based on promising preclinical studies in animals showing that ultra-high dose rate (UHDR) beam irradiations (FLASH) were sparing normal tissues while maintaining intact the effect on tumors. The first FLASH treatment of a patient was authorized by the Swiss Federal Office of Public Health for a compassionate use. The treatment was delivered with a 5.4 MeV FLASH electron linac (Oriatron, PMB France) on a cutaneous lymphoma. This treatment was delivered by a RTT who was included in the FLASH task group to give some expertise about patient interface (ie the table and treatment applicators), and machine ergonomy for the user. The clinical translation is ongoing through the IMPULSE phase I dose escalation trial (NCT 04986696) for subcutaneous metastases of melanoma. Treatments were delivered with a 9MeV UHDR Mobetron (IntraOp, California). The LANCE protocol is a second trial that was opened in 2023. It is a randomized phase II selection trial of FLASH and conventional radiotherapy for patients with localized cutaneous squamous cell carcinoma or basal cell carcinoma. The next step in the clinical transfer of FLASH RT will be the implementation of the new very high energy electron (VHEE) based linac conceived by Theryq and CERN which will allow delivery of larger UHDR field beams able to reach deeper and larger targets. The FLASH project is mostly innovative, in terms of technology, patient care, ultra-short duration of the treatment, with potential therapeutic gain and medico-economic benefits. Each professional of the Radio-oncology team plays a part in the outcome of such an ambitious program and RTTs actively contribute to various working groups.

The presentation will describe the extent and diversity of the RTTs involvement in all the aspects of the project.

3338

Focal re-irradiation

Mark Corkum

The Ottawa Hospital, Radiation Oncology, Ottawa, Canada

Abstract:

Given the potentially curative nature of salvage prostate reirradiation, in this presentation we will cover data which is supportive (and potentially refutes) the role of focal prostate reirradiation as a salvage technique. A focal reirradiation approach can be implemented in both salvage prostate SBRT as well as salvage prostate brachytherapy. Data supportive of focal reirradiation relies on the dominant intraprostatic lesion being the only site of intraprostatic